AUS
NZ
UK
CA
USA
IND
CurveBeam AI has revealed a remarkable 80% increase in customer receipts for the fourth quarter of fiscal year 2026, alongside significant progress in its China commercialisation strategy. The company is moving closer to securing regulatory approval in China, which could unlock substantial milestone payments.
Key Points
- CurveBeam AI (ASX:CVB)
- 80% growth in Q4 FY26 customer receipts
- Advancing China strategy with expected NMPA clearance in H2 2026
- Investors should watch for upcoming regulatory milestones and sales developments
CurveBeam AI Achieves 80% Growth in Q4 FY26 Customer Receipts
In Q4 FY26, CurveBeam AI reported customer receipts of A$2.58 million, marking an 80% increase from A$1.43 million in the previous quarter. This growth is credited to effective sales execution and securing purchase orders for its HiRise174; systems.
Although some advanced sales opportunities remained open at quarter-end, they are expected to contribute to purchase orders in Q1 FY27. The company entered Q1 FY27 with A$4.2 million in purchase orders and receivables, indicating a robust sales pipeline.
Progress in China Commercialisation Strategy
CurveBeam AI continues to advance its China commercialisation efforts in partnership with Weiying/WEGO Orthopaedics. During Q4 FY26, the company responded to feedback from China’s National Medical Products Administration (NMPA) regarding its HiRise174; application. NMPA clearance is anticipated in the second half of calendar year 2026.
Upon regulatory approval, CurveBeam AI expects a A$1.0 million milestone payment from Weiying/WEGO, followed by initial orders for U.S.-manufactured HiRise174; systems for distribution in China. Additional milestone payments depend on sales of the first 10 and 50 HiRise174; units, alongside product sales revenue. The company aims to establish HiRise174; as a leading weightbearing CT solution in the Chinese market.
Preparations for HiRise174; Commercial Launch in China
During the quarter, CurveBeam AI engaged in key opinion leader outreach, identified potential reference sites, and trained personnel on HiRise174; manufacturing, assembly, and service processes. These initiatives are designed to ensure a successful market launch immediately after regulatory approval.
The strong strategic alignment and commitment between CurveBeam AI and its partner underpin efforts to accelerate HiRise174; adoption across China, building on existing technology transfer and market development programs.
Enhancements to HiRise174; Validation Process
CurveBeam AI collaborated with the R&D team of a leading robotic surgery platform to improve the HiRise174; validation process. In Q4 FY26, five HiRise174; datasets—four total knee arthroplasty and one total hip arthroplasty cases—were processed successfully, meeting image quality standards and enabling accurate segmentation and landmark detection.
Following findings related to imaging artefacts, the company implemented software and hardware improvements to resolve these issues. Final validation of these enhancements is underway at two clinical sites, marking a key milestone toward completing the assessment.
Expanding Collaboration with Robotic Surgery Platforms
CurveBeam AI is broadening its partnership with a second leading robotic surgery platform to include total hip arthroplasty validation, expanding HiRise174;'s addressable market within robotic-assisted orthopaedic surgery—a rapidly growing field.
The company remains dedicated to fulfilling outstanding validation requirements and providing necessary support to complete the process, reinforcing its commitment to enhancing product offerings and strengthening its position in the medical imaging sector.
